autologous hematopoietic stem cell transplantation followed by reduced intensity allogeneic stem cell transplantation for relatively young patients with multiple myeloma
Not Applicable
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000002533
- Lead Sponsor
- The university of Tokyo Hospital,department of hematology and oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who recall approval 2.When stem cell source becomes not available 3.Patients with another severe disease 4.Patients who had received chemotherapy for maligancies other than multipul myeloma 5.Patients who is recognized as inadaptable for this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method survival rate of patients at 100 days from allotransplantation
- Secondary Outcome Measures
Name Time Method overall survival, disease free survival and cummulative incidence of acute and chronic GVHD